Intranasal Drug Delivery System Targeting Migraine

IN606629BActive Publication Date: 2026-10-22M S RAMAIAH UNIV OF APPLIED SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202041055904
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-12-22
Publication Date
2026-10-22
Estimated Expiration
2040-12-22

AI Technical Summary

Technical Problem

Conventional migraine treatments face challenges due to delayed or inconsistent absorption and low bioavailability of drugs, leading to nausea and vomiting, as they are not effectively delivered to the brain for controlled release.

Method used

A method for preparing a capsaicin-hydroxypropyl-beta-cyclodextrine inclusion complex (CAP-HP-β-CD) drug powder is developed, which is incorporated into a nasal inhaler using lavender oil, rosemary oil, menthol, camphor, and propylene glycol, allowing for controlled drug delivery to the brain through the intranasal route.

Benefits of technology

The nasal inhaler achieves controlled release of the drug to the brain, enhancing bioavailability and reducing side effects such as nausea and vomiting, thereby providing an effective treatment for migraine.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

TITLE: Intranasal Drug Delivery System Targeting Migraine ABSTRACT An intranasal delivery of capsaicin complexed with the polymer HP-ß-CD along with eutectic mixture (menthol: camphor) and volatile oils like rosemary and lavender oil. Solubility enhancement techniques were performed to increase the solubility of capsaicin by complexing with HP-ß-CD in the molar ratio 1:1, 1:3 and 1:5 and the results ascertained by solubility and Mass spectral studies. A prototype in-vitro Inhalation Pump was designed to study the amount of drug release from the inhaler during inhalation. HET-CAM Assay was performed to assess the irritation score between CNI-1 and CNI-2 complexed formulations.
Need to check novelty before this filing date? Find Prior Art

Description

FIELD OF INVENTION

[0001] The present invention relates to an Intranasal Drug Delivery System and more particularly to a method and system to develop a Intranasal Drug Delivery System Targeting Migraine which is a nasal route of administration to achieve controlled release of drug to the brain.RELATED ART

[0002] A Migraine is a chronic neurological disorder that is widely prevalent and complex. It is also a neurogenic pain developed due to a modification in a neurochemical and vascular changes in the peripheral and central nervous system. This Migraine is characterized by attacks of headache that range from moderate to severe and arises at one side of the head and gets aggregated by physical activity accompanied by nausea, vomiting, and extreme sensitivity to light and sound. This Migraine attacks last for hours to days.

[0003] The conventional migraine diagnosis depends on the patient's symptoms including where it hurts and often, they have and long it lasts. This migraine is not curable but they are treated or prevented by medications. This Migraine causes decrease in Gastrointestinal (GI) motility thereby causing delay or inconsistent absorption and low bioavailability of the conventional drugs that results in nausea and vomiting.

[0004] Hence, an effective and an efficient Intranasal Drug Delivery System is required for Migraine to achieve controlled release of drug to the brain.SUMMARY

[0005] In one embodiment, a method of preparation of a drug nasal inhaler using capsaicin-hydroxypropyl-beta-cyclodextrine inclusion complex (CAP-HP-B-CD) drug powder comprising (110): measuring an accurate amount of 1 ml of a lavender oil and 0.5 ml of a rosemary oil and adding to a 0.75 ml of a tween20 in a motor and pestle to obtain a mixture (111); adding a 2 ml of a propylene glycol and water in a ratio of 4:6 to the obtained mixture with continuous trituration in one direction to obtain a propylene glycol solution (112); adding a 0.5 g of menthol and 0.5 g of a camphor in the ratio 1:1 to form a eutectic mixture (113); adding the obtained Capsaicin-hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) drug powder to the formed eutectic mixture to obtain a eutectic complex mixture (114); adding the obtained propylene glycol to the obtained eutectic complex mixture with continuous trituration up to 10 ml to obtain a drug solution (115); and adding the obtained drug solution to a cotton plug or a wick to obtain a drugnasal inhaler (116), wherein the obtained drug nasal inhaler is used for Migraine to achieve controlled release of drug to the brain.

[0006] Several aspects are described below, with reference to diagrams. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the present disclosure. One who skilled in the relevant art, however, will readily recognize that the present disclosure can be practiced without one or more of the specific details, or with other methods, etc. In other instances, well-known structures or operations are not shown in detail to avoid obscuring the features of the present disclosure.BRIEF DESCRIPTION OF DRAWINGS

[0007] FIG. 1A is a flow chart illustrating a method of preparation of a capsaicin-hydroxypropyl-beta-cyclodextrine inclusion complex (CAP-HP-B-CD) drug powder used to prepare a drug nasal inhaler in an embodiment of the present disclosure.

[0008] FIG. 1B is a flow chart illustrating a method of preparation of a drug nasal inhaler using capsaicin-hydroxypropyl-beta-cyclodextrine inclusion complex (CAP-HP-B-CD) drug powder in an embodiment of the present disclosure.

[0009] FIG. 2A and FIG. 2B is a tabular data illustrating a composition of the prepared drug and a schematic view of a drug nasal inhaler respectively in an embodiment of the present disclosure.

[0010] FIG. 3A through FIG. 3D are a schematic views of an in-vitro inhalation pump and its units respectively in an embodiment of the present disclosure.

[0011] FIG. 4A through FIG. 4F are the images of the FTIR spectrum and IR spectral data of the capsaicin (CAP), hydroxypropyl-beta-cyclodextrin (HP-β-CD), 1:1 molar ratio of Capsaicin-hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD), 1:3 molar ratio of Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) and 1:5 molar ratio of Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) respectively in an embodiment of the present disclosure.

[0012] FIG. 5A through FIG. 5D are tabular data and a standard of a calibration curve of a capsaicin (CAP) and a hydroxypropyl-beta-cyclodextrin (HP-β-CD) respectively in an embodiment of the present disclosure.

[0013] FIG. 6A and FIG. 6B is an image illustrating a results of solubility enhancement technique performed for a different molar ratio of capsaicin (CAP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) in an embodiment of the present disclosure.

[0014] FIG. 7A and FIG. 7B are mass spectroscopy results illustrating a LCMS / MS fragmentation pattern of drug Capsaicin with polymer in the ratio of 1:3 and 1:5 respectively in an embodiment of the present disclosure.

[0015] FIG. 8A through FIG. 8D are images illustrating the results of a HET-CAM assay (Hen's Egg Test-Chorio Allantoic Membrane) of different samples of the drug complex to detect the irritation severity in an embodiment of the present disclosure.DETAILED DESCRIPTION OF THE PREFERRED EXAMPLES

[0016] FIG. 1A is a flow chart illustrating a method of preparation of a capsaicin-hydroxypropyl-beta-cyclodextrine inclusion complex (CAP-HP-B-CD) drug powder used to prepare a drug nasal inhaler in an embodiment of the present disclosure. As shown in 100, in step 101, a capsaicin (CAP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) are weighed accurately in the ratio 1:1, 1:3 and 1:5 molar ratios respectively. In step 102, the capsaicin (CAP) is dissolved in an ethanol and hydroxypropyl-beta-cyclodextrin (HP-β-CD) in distilled water separately to obtain a capsaicin (CAP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) solutions. In step 103, the capsaicin (CAP) solution is added into the hydroxypropyl-beta-cyclodextrin (HP-β-CD) solution and stirred continuously with the aid of a magnetic stirrer for a period of 45 minutes in a closed condition to obtain a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) mixture. In step 104, the obtained capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) mixture is ultrasonicated further for 15 minutes to obtain an inclusion complex of capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD). In step 105, the obtained inclusion complex of a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) is dried through different drying techniques to obtain a Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) drug powder.

[0017] In an embodiment, the different drying techniques used are hot-air oven, lyophilization and rota-evaporator. In hot-air oven drying techniques, the obtained inclusion complex of a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) is placed in the Hot-Air oven for 30 minutes at 400 °C. The temperature is maintained at 400 °C to avoid degradation of the drug. The dried product is scraped out and the percentage yield is calculated.

[0018] The lyophilization drying techniques works on the principle of sublimation where the liquid substance is freezed and transformed to a solid which is lyophilized to evaporate the vapors and the dry substance obtained. The obtained inclusion complex of a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) is transferred to the Eppendorf tubes and is placed in the freezer for 24 hours. The frozen mixture is placed in the lyophilizer at -540 °C for a period 48 hours. The dried product is easily scraped out and percentage yield was calculated.

[0019] The rota-evaporator drying techniques works by increasing the rate of evaporation of the solvent by reducing the pressure to lower the boiling point of the solvent and by rotating the sample to increase the surface area by heating the solution. The obtained inclusion complex of a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) is transferred to a round bottom flask (RBF) which is subjected to solvent evaporation at 850 C under vacuum to form a thin film. The film is scraped and the percentage yield is calculated.

[0020] FIG. 1B is a flow chart illustrating a method of preparation of a drug nasal inhaler using capsaicin-hydroxypropyl-beta-cyclodextrine inclusion complex (CAP-HP-B-CD) drug powder in an embodiment of the present disclosure. As shown in 100, in step 111, an accurate amount of 1 ml of a lavender oil and 0.5 ml of a rosemary oil are measured and added to a 0.75 ml of a tween20 in a motor and pestle to obtain a mixture. In step 112, a 2 ml of a propylene glycol and water in a ratio of 4:6 is added to the obtained mixture with continuous trituration in one direction to obtain a propylene glycol solution. In step 113, a 0.5 g of menthol and 0.5 g of a camphor in the ratio 1:1 is added to form a eutectic mixture. In step 114, the obtained Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) drug powder is added to the formed eutectic mixture to obtain a eutectic complex mixture. In step 115, the obtained propylene glycol is added to the obtained eutectic complex mixture with continuous trituration up to 10 ml to obtain a drug solution. In step 116, the obtained drug solution is added to a cotton plug or a wick to obtain a drug nasal inhaler. This drug nasal inhaler is used for Migraine to achieve controlled release of drug to the brain.

[0021] FIG. 2A and FIG. 2B is a tabular data illustrating a composition of the prepared drug and a schematic view of a drug nasal inhaler respectively in an embodiment of the present disclosure. As shown in 200, shows that the concentration of capsaicin used in the composition is varied from 0.013 % to 0.1% (w / v). Thus, 0.1% (w / v) of capsaicin is selected because there is no direct contact between the drug and nasal mucosa, thus a higher dose of drug is required to be inhaled from the nasal inhaler. The nasal drug comprises of a 10 mg equivalent inclusion complex of a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD), 1 ml of lavender oil, 0.5 ml of rosemary oil,0.5 g of menthol,0.5 g of camphor, 0.75 ml of tween20 and a propylene glycol in the ratio 4:6 quantity sufficient to 10 ml.

[0022] Therefore, (0.1w / v) loading dose is selected where 100ml contains 100mg of a drug (0.1w / v) i.e., 2.5ml contains 2.5mg of equivalent inclusion complex of a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) which means 1 drop of solution contains = 0.06ml. And, 42 drops of solution contain 2.5ml. Thus, 42 drops of the formulation containing 2.5 mg of drug equivalent loaded into Nasal stick wick.

[0023] As shown in 210, is a drug nasal inhaler is a drug delivery system to treat respiratory and transport drug from nose to brain. It comprises of a seal cap 212, a cotton wick 214, an inhaler 216 and a container 218. The seal cap is used to secure a cotton wick 214 inside an inhaler from falling out and is snapped it into the bottom of the nasal inhaler after the cotton wick 214 is placed back. The cotton wick 214 is a piece where 42 drops of the prepared drug solution is added and inserted inside the inhaler 216. The inhaler 216 is tightly screwed into the container 218 and is used as drug nasal inhaler to inhale the drug for Migraine to achieve controlled release of drug to the brain. The container 218 fits over the inhaler to keep it clean and prevent the aromatic vapors of the drug from escaping.

[0024] In an embodiment, the volume of the cotton wick is calculated to ascertain the amount of drug solution required to be added into the cotton wick.Volume of cylinder (V) = πr2hRadius (r)=0.35Height (h)= 3.3V= 3.14*(0.35)2*3.3=1.27 cm2

[0025] Thus,1.27 cm2 incorporate 42 drops of the drug solution which is equivalent to 2.5 ml.

[0026] FIG. 3A through FIG. 3D are a schematic views of an in-vitro inhalation pump and its units respectively in an embodiment of the present disclosure. As shown in 300, is an in-vitro inhalation pump used to calculate the amount of drug released from the nasal inhaler after every inhalation. It is a device that mimics the inhalation pattern of the lungs. It comprises of a airbag unit 302, a piston unit 304, a slider crank unit 306, a motor unit 308, a power unit 310, a switch unit 312 and a inhaler unit 314.Each unit is explained in detail below.

[0027] The airbag unit 302 is used to perform a suction process of the drug from the inhaler unit 314.

[0028] The piston unit slides back and forth is connected to a semicircular object used for applying pressure on to the airbag unit 302.

[0029] The slider crank unit 306 is used to convert straight line motion to rotary motion and vice versa.

[0030] The motor unit 308 converts electrical energy to mechanical energy. A wiper motor is used which is a small electric motor where a power output obtained from motor unit 308 is used for driving the crankshaft and hence the piston movement which gives the suction effect.

[0031] The power unit 310 to activate the entire device where a chargeable / rechargeable DC 12-volt battery is used. The electricity required for producing the required mechanical power by the motor unit 308 is performed with the help of battery.

[0032] The switch unit 312 is used for controlling the functioning of the motor unit 308. The motor is switched ON / OFF position using this unit.

[0033] The inhaler unit 314 is connected to the airbag unit 302 to suck the drug particles from this unit.

[0034] As shown in 320, the process of suction of drug from the inhaler unit 315 by the air bag is performed by the piston unit 304 which slides back and forth. The semicircular object placed at the top of the piston unit 304 helps in applying pressure on the airbag (contraction= compression) and thus helps in sucking the drug during the expansion (return stroke of piston). A substantiate amount of drug that is required to be measured is sent into the airbag unit 302. The drug particles move out of the airbag unit 302 through the outlet 318 connected at the other open end of the airbag unit 302.The slider crank unit 306 which moves back and forth is operated with the help of a motor unit 308 powered by a power unit 310 controlled by a switch unit 312 to ON / OFF the device. The emptying of the content inside the inhaler unit 314 is measured by counting the number of times the slider crank unit 306 applies pressure and the airbag unit 302 expands for sucking in the gas inside. Once the weight of the cotton wick inside the inhaler unit 314 becomes negligible, then its assumed that the air has been sucked inside completely.

[0035] As shown in 330, is a self-inflating bag or the airbag unit 302 of the in-vitro inhalation pump that automatically inflates itself without any compressed gas source. It is a non-rebreathing silicon bag which is connected to oxygen intake valve 332, pressure relief valve 334, patient outlet 318 and oxygen inlet 316. Through the intake valve 332 and oxygen inlet 316, air and additional oxygen is supplied. The gas enters into the self-inflating bag or the airbag unit 302 through one end of the valve 3332 which restricts the back flow of air from the inlet 316. Once the bag is compressed, the air inside the bag is pushed forward.

[0036] As shown in 340, the mechanism used in the slider crank unit 306 is slider crank mechanism. The mechanical parts are arranged and designed to convert straight line motion to rotary motion and vice versa. It depicts the basic nature of the mechanism and the relative motion of the parts. The cylinder or fused frame in which the piston unit 304 slides back and forth. The Crankshaft connects the main bearing 'A' to crankpin bearing 'B'. A connecting rod is present between crankshaft and piston unit 304. The bearings are used for the free rotation of one part with respect to the other. The piston unit 304 which slides back and forth is connected to a semicircular object which is used for applying pressure on to the airbag unit 302.

[0037] FIG. 4A through FIG. 4F are the images of the FTIR spectrum and IR spectral data of the capsaicin (CAP), hydroxypropyl-beta-cyclodextrin (HP-β-CD), 1:1 molar ratio of Capsaicin-hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD), 1:3 molar ratio of Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) and 1:5 molar ratio of Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) respectively in an embodiment of the present disclosure. As shown in 400 through 404, are FT-IR studies conducted to the study inclusion of the drug sample within the complexing agent. As shown in 400, is a FT-IR spectra of the drug sample where in bending and vibrations in finger print regioni.e.,3660 cm-1 ,2993 cm-1,3300 cm-1,3065 cm-1,1564 cm-1 attributed to OH stretch (phenolic), CH3 stretch, Aromatic C-H and Aromatic C=C accordingly. As shown in 400, is a spectrum of HP-β-CD where in bending vibrations in finger print region i.e., 3660 cm-1,1465 cm-1, 1285 cm-1and 1120 cm-1 attributed to OH stretch, CH2 bend, C-O stretch and C-O-C stretch. Thus, from the study it was observed that the Capsaicin is enclosed with HP-β-CD in the ratios of 1:1, 1:3 and 1:5.

[0038] FIG. 5A through FIG. 5D are tabular data and a standard of a calibration curve of a capsaicin (CAP) and a hydroxypropyl-beta-cyclodextrin (HP-β-CD) respectively in an embodiment of the present disclosure. As shown in 500 and 510, are tabular data and a standard of a calibration curve of a capsaicin (CAP). As shown in 520 and 530, are tabular data and a standard of a calibration curve of a hydroxypropyl-beta-cyclodextrin (HP-β-CD).

[0039] FIG. 6A and FIG. 6B is an image illustrating a results of solubility enhancement technique performed for a different molar ratio of capsaicin (CAP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) in an embodiment of the present disclosure. As shown in 600, is a solubility enhancement technique performed to increase the solubility of capsaicin which is insoluble in water. It is complexed with Hydroxypropyl-beta-Cyclodextrin (HP-β-CD) in different molar ratios of 1:1, 1:3 and 1:5. The solubility of capsaicin in water is 28.98 mg / L.

[0040] As shown in 610, where a drug complex is prepared in the molar ratio 1:1 and the drying technique utilized is hot air-drying method. The percentage yield obtained is 25% and the solubility is found to 52.36mg / L. The percentage yield is less and the complex produced irritation. However, solubility is improved when compared to pure capsaicin. Since the irritation persisted similar to pure capsaicin, 1:1 molar ratio is not chosen for suitable for drug preparation.

[0041] In an embodiment, the inclusion complex in the ratio 1:3 produced better percentage yield and solubility when compared to 1:1 molar ratio. The Hot air oven method resulted in 56.6% percentage yield and solubility of 65.53mg / L. Similarly, the percentage yield by lyophilization is 69% and solubility 72.47mg / L. The Drying the product by lyophilization produced better yield and solubility is greater compared to hot air method. The Drying the complex by Rota-evaporator exhibited 67.2% percentage yield and 70.4 mg / L solubility which is higher when compared to hot air oven method and lesser when compared to Lyophilization method.

[0042] In an embodiment, the inclusion complex of 1:5 molar ratio, dried by hot air oven produced a percentage yield of 62.5% and the solubility is 60.5mg / L. Then the lyophilized product percentage yield is 79% which is the highest among other methods and the solubility is found to be 74.67mg / L which is considered to have good solubility. The complex is dried by rota evaporator drying method and the percentage yield is found to be 70% and the solubility is 61.05 mg / L. The complex dried via rota -evaporator proved to have better solubility and the irritation subsided when compared to pure capsaicin.

[0043] In an embodiment, the pH of the different molar ratio of capsaicin (CAP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) are determined by digital pH meter. The solution is taken in a 50ml beaker and subjected to estimation of pH. The pH of 1:3 and 1:5 molar ratio of capsaicin (CAP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) is 5.32 and 5.5 respectively.

[0044] FIG. 7A and FIG. 7B are mass spectroscopy results illustrating a LCMS / MS fragmentation pattern of drug Capsaicin with polymer in the ratio of 1:3 and 1:5 respectively in an embodiment of the present disclosure. As shown in 700 and 710, is a Mass spectroscopy which is performed to study the mass to charge ratios of the ions. The molar ratio 1:3 and 1:5 is subjected to mass spectroscopy. It shows LCMS / MS fragmentation pattern of drug Capsaicin with polymer in the ratio of 1:3 and 1:5. The following observations are recorded as per the mass interpretation. A prominent fragmented ion was present at 306m / z. An adduct fragmented ion was present at 612 m / z The Hydroxylpropyl-Beta-Cyclodextrin showed a fragmented peak at 1389.66m / z. For the molar ratio 1:3 and a fragmented peak of 1447.45m / z for the molar ratio 1:5. The fragmented ion at 1389.66 m / z (1:3) and 1447.45m / z (1:5) gives a clue that Hydroxypropyl -Beta- Cyclodextrin is present in the mixture which is represented by formula HP4-β-CD and HP5-β-CD with the loss of beta hydroxy propyl group. An adduct fragmented ion at 612 m / z shows that capsaicin is embedded in Hydroxypropyl-Beta-Cyclodextrin. The Prominent fragment ion at 306m / z confirms the presence of the drug Capsaicin as it matches with the standard molecular weight of the compound 306 g / mol.

[0045] FIG. 8A through FIG. 8D are images illustrating the results of a HET-CAM assay (Hen's Egg Test-Chorio Allantoic Membrane) of different samples of the drug complex to detect the irritation severity in an embodiment of the present disclosure. As shown in 800 through 830, is a HET-CAM assay (Hen's Egg Test-Chorio Allantoic Membrane) test conducted to detect the irritation severity of the test samples of the drug complex. The potential degree of irritancy of the test samples are measured by its ability to induce toxicity to the CAM (Chorio Allantoic membrane) of a chick embryo. The test is divided into four groups. A Positive control, test samples (1:3 capsaicin formulation and 1:5 capsaicin formulation) and the negative control is subjected to irritation scoring. The mean irritation scores for 1:3 and 1:5 capsaicin formulations is found to be 2.37 and 1, both the test samples belong to the class of slight irritant. The irritation created on the blood vessel is less when compared to the positive control. The mean irritation score for 0.1N NaOH (positive control) is found to be 11.96, while that of 0.9%NaCl w / v (negative control) is found to be 0.

[0046] While various embodiments of the present disclosure have been described above, it should be understood that they have been presented by way of example only, and not limitation. Thus, the breadth and scope of the present disclosure should not be limited by any of the above- discussed embodiments, but should be defined only in accordance with the following claims and their equivalents.

Claims

1. A method of preparation of a capsaicin-hydroxypropyl-beta-cyclodextrine inclusion complex (CAP-HP-B-CD) drug powder comprising (100): weighing accurately a capsaicin (CAP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) in the ratio 1:1, 1:3 and 1:5 molar ratios respectively (101); dissolving the capsaicin (CAP) in an ethanol and hydroxypropyl-beta-cyclodextrin (HP-β-CD) in distilled water separately to obtain a capsaicin (CAP) and hydroxypropyl-beta-cyclodextrin (HP-β-CD) solutions (102); adding the capsaicin (CAP) solution into the hydroxypropyl-beta-cyclodextrin (HP-β-CD) solution and stirred continuously with the aid of a magnetic stirrer for a period of 45 minutes in a closed condition to obtain a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) mixture (103); ultrasonicating the obtained capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) mixture for 15 minutes to obtain an inclusion complex of capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) (104); and drying the obtained inclusion complex of a capsaicin-hydroxypropyl-beta-cyclodextrin (CAP-HP-β-CD) through different drying techniques to obtain a Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) drug powder (105), wherein the obtained Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) drug powder is used to prepare drug nasal inhaler for Migraine.

2. A method of preparation of a drug nasal inhaler using capsaicin-hydroxypropyl-beta-cyclodextrine inclusion complex (CAP-HP-B-CD) drug powder comprising (110): measuring an accurate amount of 1 ml of a lavender oil and 0.5 ml of a rosemary oil and adding to a 0.75 ml of a tween20 in a motor and pestle to obtain a mixture (111); adding a 2 ml of a propylene glycol and water in a ratio of 4:6 to the obtained mixture with continuous trituration in one direction to obtain a propylene glycol solution (112); adding a 0.5 g of menthol and 0.5 g of a camphor in the ratio 1:1 to form a eutectic mixture (113); adding the obtained Capsaicin- hydroxypropyl-beta-Cyclodextrin inclusion complex (CAP-HP-β-CD) drug powder to the formed eutectic mixture to obtain a eutectic complex mixture (114); adding the obtained propylene glycol to the obtained eutectic complex mixture with continuous trituration up to 10 ml to obtain a drug solution (115); and adding the obtained drug solution to a cotton plug or a wick to obtain a drug nasal inhaler (116), wherein the obtained drug nasal inhaler is used for Migraine to achieve controlled release of drug to the brain.

3. A drug nasal inhaler (210) comprising: a seal cap is used to secure a cotton wick (214) inside an inhaler 216 from falling out and is snapped it into the bottom of an inhaler (216) after the cotton wick (214) is placed back; a cotton wick (214) is a piece where 42 drops of the prepared drug solution is added and inserted inside an inhaler (216); an inhaler (216) is tightly screwed into the container (218); and a container (218) fits over the inhaler to keep it clean and prevent the aromatic vapors of the drug from escaping, wherein the drug nasal inhaler (210) is used for Migraine to achieve controlled release of drug to the brain.

4. Method, system and apparatus providing one or more features as described in the paragraphs of this specification.